The present invention provides a novel compound having FGFR inhibitory activity or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition containing the same. Specifically, the present invention provides a compound represented by the following formula (I) or a pharmaceutically acceptable salt thereof:wherein n represents 0 to 2 A represents an arylene group or a heteroarylene group G represents a single bond, an oxygen atom or —CH2— E represents a nitrogen-containing non-aromatic heterocycle R1 represents an alkoxy group or the like R2 represents a hydrogen atom or the like and R3 represents a hydrogen atom, an alkyl group, an alkoxy group or the like, with the proviso that when E represents an azetidine ring and R2 or R3 is present on a nitrogen atom on the azetidine ring, the R2 or R3 does not represent a hydrogen atom.
